retatrutide weight loss results clinical trials VisualAbstract: reduces body by 17.5% in patients with obesity Retatrutide Weight Loss Results:Trial Data
Description
Professional Medical Disclaimer This article is educational and does not constitute medical advice
The brand states this explicitly
Its structure is a continuous escalation-then-maintenance arc: Initiation phase (weeks 14): 2.5 mg weekly
In 2022 alone, nine million Americans were prescribed Ozempic, and that could rise to 24 million in the next decade, according to analysis by Morgan Stanley
Novo Nordisk submitted CagriSema to the FDA in December 2025, with a decision expected in late 2026 and UK availability likely in 2027 or later
